Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate
To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols.
| Condition(s) | Prostate Cancer, Magnetic Resonance Imaging, Population at Risk |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | To determine whether using bpMRI in subjects who are at high risk of developing prostate cancer in conjunction with PSA will improve prostate cancer screening protocols. |
| Who can participate | Inclusion Criteria: 1. PSA between 1.0 and 2.5 ng/dL 2. High risk for prostate cancer, i.e. Black or they have a first degree relative with history of prostate cancer (father, brother) or specific genetic syndromes i.e. BRCA 1/2, HOX B13, Lynch syndrome, ATM, CHEK2 3. Patient is willing to participated in prostate cancer screening 4. Patient is capable of giving informed consent Exclusion Criteria: 1. Nodularity or firmness of prostate on exam 2. Patient has undergone a prior biopsy or prostate surgery 3. Patient is taking 5-alpha reductase inhibitors to manage benign prostatic hyperplasia, as this can significantly alter PSA levels. 4. Patient has a history of UTI or prostatitis in the preceding 6 months, as this can significantly alter PSA levels. 5. Patient has a contraindication to MRI |
| Ages | 40 Years to 55 Years |
| Sex | Male |
| Lead sponsor | Northwell Health |
| Locations | Lake Success, New York, United States |
| Start date | 2022-08-15 |
| NCT ID | NCT05384535 |
| Official listing | https://clinicaltrials.gov/study/NCT05384535 |